{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:52:30Z","timestamp":1781758350503,"version":"3.54.5"},"reference-count":72,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Statins are widely used to inhibit cholesterol synthesis and help prevent cardiovascular diseases associated with elevated blood cholesterol levels. Several clinical trials have shown that some of the benefits observed with statins are independent of cholesterol lowering. Part of these pleiotropic effects is related to the ability of statins to directly interact with and alter the physical properties of lipid membranes such as lipid packing and, consequently, membrane fluidity. Membrane lipid therapy is an innovative approach based on the use of drugs with the potential to change membrane lipid structure for therapeutic purposes, including enhancing the intracellular delivery of chemotherapeutic drugs. Evidence from studies using both artificial model membranes and biological membranes supports the potential use of statins as effective drug candidates for membrane lipid therapy. However, the transition from the promising in vitro results to the clinical practice has encountered significant challenges. This commentary highlights the pitfalls in repurposing statins as membrane-modifying agents.<\/jats:p>","DOI":"10.3390\/ijms27125303","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:53:10Z","timestamp":1781247190000},"page":"5303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statins in Membrane Lipid Therapy: Mechanistic Promise Versus Clinical Reality"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8318-4698","authenticated-orcid":false,"given":"Giulio","family":"Preta","sequence":"first","affiliation":[{"name":"Institute of Biochemistry, Life Sciences Center, Vilnius University, Saul\u0117tekio av. 7, LT-10257 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: Far beyond new targets for old drugs","volume":"14","author":"Oprea","year":"2012","journal-title":"AAPS J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: A repurposed drug to fight cancer","volume":"40","author":"Jiang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2025.10.003","article-title":"Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology","volume":"117","author":"Abdelhamid","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1158\/1078-0432.CCR-20-1967","article-title":"Statins as Anticancer Agents in the Era of Precision Medicine","volume":"26","author":"Longo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1016\/j.jmb.2016.08.022","article-title":"The Continuing Mystery of Lipid Rafts","volume":"428","author":"Levental","year":"2016","journal-title":"J. Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12944-025-02563-0","article-title":"Lipid rafts: Novel therapeutic targets for metabolic, neurodegenerative, oncological, and cardiovascular diseases","volume":"24","author":"Warda","year":"2025","journal-title":"Lipids Health Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1194\/jlr.TR119000439","article-title":"Lipid rafts as signaling hubs in cancer cell survival\/death and invasion: Implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts","volume":"61","author":"Mollinedo","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood.V98.13.3860","article-title":"The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas\/CD95 into membrane rafts in human leukemic cells","volume":"98","author":"Gajate","year":"2001","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14833","DOI":"10.1074\/jbc.M511251200","article-title":"Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells","volume":"281","author":"Gajate","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1021\/acs.jpcb.3c02574","article-title":"Statin Action Targets Lipid Rafts of Cell Membranes: GIXD\/PM-IRRAS Investigation of Langmuir Monolayers","volume":"127","author":"Zaborowska","year":"2023","journal-title":"J. Phys. Chem. B"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22050","DOI":"10.1073\/pnas.1016184107","article-title":"Palmitoylation regulates raft affinity for the majority of integral raft proteins","volume":"107","author":"Levental","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbamem.2017.01.030","article-title":"Sizes of lipid domains: What do we know from artificial lipid membranes? What are the possible shared features with membrane rafts in cells?","volume":"1859","author":"Rosetti","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fphar.2017.00012","article-title":"Targeting Membrane Lipid a Potential Cancer Cure?","volume":"8","author":"Tan","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S134834","article-title":"Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer","volume":"7","author":"Belzile","year":"2018","journal-title":"Immunotargets Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41467-019-09654-4","article-title":"Ceramides bind VDAC2 to trigger mitochondrial apoptosis","volume":"10","author":"Dadsena","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yura, Y., Masui, A., and Hamada, M. (2020). Inhibitors of Ceramide- and Sphingosine-Metabolizing Enzymes as Sensitizers in Radiotherapy and Chemotherapy for Head and Neck Squamous Cell Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12082062"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00280-007-0465-0","article-title":"Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells","volume":"61","author":"Holman","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2016.10.008","article-title":"Cell membrane modulation as adjuvant in cancer therapy","volume":"52","author":"Zalba","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.plipres.2015.04.003","article-title":"Membrane lipid therapy: Modulation of the cell membrane composition and structure as a molecular base for drug discovery and new disease treatment","volume":"59","author":"Escriba","year":"2015","journal-title":"Prog. Lipid Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1124\/mol.104.000778","article-title":"Membrane structure modulation, protein kinase C\u03b1 activation, and anticancer activity of Minerval","volume":"67","author":"Casas","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19569","DOI":"10.1073\/pnas.1115484108","article-title":"Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy","volume":"108","author":"Martin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.bbamem.2013.06.014","article-title":"Partitioning of liquid-ordered\/liquid-disordered membrane microdomains induced by the fluidifying effect of 2-hydroxylated fatty acid derivatives","volume":"1828","author":"Ibarguren","year":"2013","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.molliq.2019.03.143","article-title":"The influence of 2-hydroxyoleic acid\u2014An anticancer drug\u2014On model membranes of different fluidity modulated by the cholesterol content","volume":"283","author":"Olechowska","year":"2019","journal-title":"J. Mol. Liq."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18328","DOI":"10.1074\/jbc.RA118.005904","article-title":"2-Hydroxy-oleic acid does not activate sphingomyelin synthase activity","volume":"293","author":"Lou","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/s41598-019-41903-w","article-title":"The asymmetry of plasma membranes and their cholesterol content influence the uptake of cisplatin","volume":"9","author":"Rivel","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bbamem.2017.05.017","article-title":"Membrane-lipid therapy: A historical perspective of membrane-targeted therapies\u2014From lipid bilayer structure to the pathophysiological regulation of cells","volume":"1859","author":"Escriba","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.str.2017.02.007","article-title":"Computational Modeling Reveals that Signaling Lipids Modulate the Orientation of K-Ras4A at the Membrane Reflecting Protein Topology","volume":"25","author":"Li","year":"2017","journal-title":"Structure"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e201900431","DOI":"10.26508\/lsa.201900431","article-title":"Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function","volume":"2","author":"Kattan","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41392-025-02473-8","article-title":"Targeting KRAS mutations: Orchestrating cancer evolution and therapeutic challenges","volume":"10","author":"Choucair","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u2018undruggable\u2019 cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Torres, M., Rossello, C.A., Fernandez-Garcia, P., Llado, V., Kakhlon, O., and Escriba, P.V. (2020). The Implications for Cells of the Lipid Switches Driven by Protein-Membrane Interactions and the Development of Membrane Lipid Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072322"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jbior.2014.10.003","article-title":"Lipid rafts as major platforms for signaling regulation in cancer","volume":"57","author":"Mollinedo","year":"2015","journal-title":"Adv. Biol. Regul."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bpj.2016.06.016","article-title":"Effect of Statins on the Nanomechanical Properties of Supported Lipid Bilayers","volume":"111","author":"Andersen","year":"2016","journal-title":"Biophys. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1021\/acsbiomaterials.4c00911","article-title":"Influence of Simvastatin and Pravastatin on the Biophysical Properties of Model Lipid Bilayers and Plasma Membranes of Live Cells","volume":"10","author":"Polita","year":"2024","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.addr.2013.09.004","article-title":"Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles","volume":"65","author":"Peetla","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12032-023-02248-7","article-title":"Enhanced therapeutic efficacy of doxorubicin\/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells","volume":"41","author":"Dewidar","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12032-022-01733-9","article-title":"Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells","volume":"39","author":"Crown","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mangelinck, A., Habel, N., Mohr, A., Gaspar, N., Stefanovska, B., and Fromigue, O. (2021). Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma. Cancers, 13.","DOI":"10.3390\/cancers13225869"},{"key":"ref_39","first-page":"e2078","article-title":"Statins as anti-tumor agents: A paradigm for repurposed drugs","volume":"7","author":"Tripathi","year":"2024","journal-title":"Cancer Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biochi.2018.11.011","article-title":"Biological applications of tethered bilayer lipid membranes","volume":"157","author":"Penkauskas","year":"2019","journal-title":"Biochimie"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chembiol.2013.11.009","article-title":"Fluorescent probes for lipid rafts: From model membranes to living cells","volume":"21","author":"Klymchenko","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-pharmtox-010919-023411","article-title":"Lipid-Dependent Regulation of Ion Channels and G Protein-Coupled Receptors: Insights from Structures and Simulations","volume":"60","author":"Duncan","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbamem.2018.12.013","article-title":"Interaction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy","volume":"1861","author":"Galiullina","year":"2019","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11F","DOI":"10.1016\/j.amjcard.2005.06.008","article-title":"Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions","volume":"96","author":"Mason","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","article-title":"Organic anion transporting polypeptides of the OATP\/SLC21 family: Phylogenetic classification as OATP\/SLCO superfamily, new nomenclature and molecular\/functional properties","volume":"447","author":"Hagenbuch","year":"2004","journal-title":"Pfl\u00fcgers Arch."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/jpet.106.106591","article-title":"Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver","volume":"319","author":"Libra","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4161\/cbt.11.6.14533","article-title":"Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue","volume":"11","author":"Kindla","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"ref_49","first-page":"1180","article-title":"Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase","volume":"14","author":"Kato","year":"2010","journal-title":"J. Cell Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Glebaviciute, G., Vijaya, A.K., and Preta, G. (2024). Effect of Statin Lipophilicity on the Proliferation of Hepatocellular Carcinoma Cells. Biology, 13.","DOI":"10.3390\/biology13060455"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.21037\/jtd-2025-66","article-title":"Statins as potential adjuvant therapy in lung cancer: A narrative review","volume":"17","author":"Tian","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: A critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107912","DOI":"10.1016\/j.phrs.2025.107912","article-title":"Statin drugs and lipid modulation: Mechanistic basis considering lipid rafts, kinase signaling, myopathy, and cancer","volume":"220","author":"Karthikeyan","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.atherosclerosis.2015.03.025","article-title":"Genetic and immunologic susceptibility to statin-related myopathy","volume":"240","author":"Patel","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e202500533","DOI":"10.1002\/open.202500533","article-title":"Computational Evaluation of Statin Analogs Targeting HMG-CoA Reductase for Coronary Artery Disease Treatment","volume":"15","author":"Mtulo","year":"2026","journal-title":"ChemistryOpen"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1016\/j.bmc.2007.05.031","article-title":"Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase","volume":"15","author":"Bratton","year":"2007","journal-title":"Bioorg Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.bmcl.2007.11.124","article-title":"Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors","volume":"18","author":"Park","year":"2008","journal-title":"Bioorg Med. Chem. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12032-025-03101-9","article-title":"Statins in the context of precision cancer medicine: Important factors to consider","volume":"42","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Murphy, C., Deplazes, E., Cranfield, C.G., and Garcia, A. (2020). The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228745"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11830","DOI":"10.1038\/s41598-024-62615-w","article-title":"Highly variable biological effects of statins on cancer, non-cancer, and stem cells in vitro","volume":"14","author":"Gbelcova","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13201","DOI":"10.2147\/OTT.S283033","article-title":"Comparative Study of Lipophilic Statin Activity in 2D and 3D in vitro Models of Human Breast Cancer Cell Lines MDA-MB-231 and MCF-7","volume":"13","author":"Bytautaite","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.2147\/DDDT.S149411","article-title":"Differences of statin activity in 2D and 3D pancreatic cancer cell cultures","volume":"11","author":"Paskeviciute","year":"2017","journal-title":"Drug Des. Devel Ther."},{"key":"ref_66","first-page":"2553","article-title":"The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: In 3D in Vitro Model","volume":"19","author":"Bayat","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbrc.2017.05.147","article-title":"Atorvastatin augments temozolomide\u2019s efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling","volume":"489","author":"Peng","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.stem.2025.07.008","article-title":"A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy","volume":"32","author":"Li","year":"2025","journal-title":"Cell Stem Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0006-2952(02)01654-4","article-title":"Statin effects on cholesterol micro-domains in brain plasma membranes","volume":"65","author":"Kirsch","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"590","DOI":"10.31083\/ph.2013.6529","article-title":"Simvastatin alters membrane cholesterol distribution and beta-amyloid levels in brains of female APP751SL mice","volume":"68","author":"Eckert","year":"2013","journal-title":"Pharmazie"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.clinthera.2007.08.010","article-title":"The effect of simvastatin on erythrocyte membrane fluidity during oxidative stress induced by cardiopulmonary bypass: A Randomized controlled study","volume":"29","author":"Coccia","year":"2007","journal-title":"Clin. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pharep.2017.11.004","article-title":"Comparison of the effects of rosuvastatin monotherapy and atorvastatin-ezetimibe combined therapy on the structure of erythrocyte membranes in patients with coronary artery disease","volume":"70","author":"Jackowska","year":"2018","journal-title":"Pharmacol. Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:14:56Z","timestamp":1781756096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":72,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27125303"],"URL":"https:\/\/doi.org\/10.3390\/ijms27125303","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}